Question-Based Review: An FDA Reviewer's Perspective - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Question-Based Review: An FDA Reviewer's Perspective
The author analyzes, from an agency perspective, whether question-based review has improved product quality or made the review process easier for regulators or for industry.


Pharmaceutical Technology
Volume 33, Issue 10

Facilitating continuous improvement and reducing CMC supplements

Unfortunately for both reviewers and sponsors, the benefit of a reduced supplement burden facilitated by the increased process and product understanding has not yet materialized.

Record numbers of original and supplemental applications continue to tax available review resources, and the need for relief has never been greater. The reduction in the number of supplements was a major element in the original QbR initiative. Unlike the overall positive effects on the knowledge base included in submissions and the increased quality and consistency in CMC reviews, substantial progress has not been made in this area. Progress and implementation by the agency of this key aspect of QbR should be a priority in the future.

That being said, the goal of supplement relief is inextricably linked to the demonstration of a high level of process understanding by the sponsor (i.e., a low-risk application). Presently, only a small number of applications for nonsimple dosage forms would qualify as low-risk because most lack demonstrable product and process understanding. Sponsors should continue to incorporate QbD principles in their product and process development and improve the quality of their PDRs in the hope that a supplement relief mechanism will become a reality in the near future.

Enhancing the quality, transparency, and consistency of reviews

Transparency in the review process has increased substantially for both the agency and industry under QbR. Agency communications, workshops, QOS examples, and guidance in the form of lists of frequently asked questions demonstrate the high level of open communication and transparency incorporated into QbR from the outset (1, 2, 6–8). OGD's expectations for documentation and the primary focus of the reviews on "quality designed into the product" have been clearly and consistently communicated to industry. QbR has increased transparency in the submissions as well. The development information, which was previously a black box in most submissions before QbR, is now fully integrated into the submissions. From a reviewer's perspective, the more information included in ANDA submissions in this regard, the better.

QbR questions have increased the quality of CMC reviews by shifting the focus of the review to areas that are most likely to affect product quality for a particular drug product. By incorporating QbD into the submission, reviews are now knowledge-based rather than requirement-based. The increase in product and process knowledge allows reviewers to identify deficiencies that are directly linked to critical product-quality issues, the resolution of which should yield a better product at the time of approval. Approving better products is really the goal of a quality-review process.

The clear format of the QOS and the corresponding review template have provided a framework that has increased review consistency. Review content and focus previously varied according to the drug product, submission quality, and the individual reviewer, team, and division assigned to the application. Variability in the content of reviews was sometimes substantial. Consistency of reviews is of particular importance for OGD because the receipt of 20 or more applications for a given product is common and can of necessity involve multiple reviewers at several review divisions. The specificity incorporated into the standardized format of the QbR ensures that critical areas remain the central focus in every review.

Reducing CMC review time

The QbR has significantly increased the amount of material covered in the CMC review, and thus, the time for the initial CMC review is marginally longer. The positive effect of QbR on review efficiency is seen in the reduced number of review cycles when the sponsor demonstrates process and product understanding. Because the critical QbR questions are designed to focus the submission on product quality and understanding, reviewers naturally spend more time focused on high-impact issues for a particular product. This focus has allowed deficiency letters to concentrate on issues of primary importance to product quality and enables the reviewer to be much more specific. When the sponsor provides a high-quality product-development report that provides a clear scientific rationale for the process and testing decisions in the submission, many of the common issues and questions previously raised by reviewers are already answered, and the deficiency letters often contain fewer items. Highly focused and short deficiency letters, coupled with an increased comfort level with the sponsor's knowledge base, increases teleconferences and allows issues to be resolved more quickly.

For OGD, the CMC review serves as an informative document that summarizes the important information about the drug product and, more importantly, as a critical evaluation of product quality. In terms of the informative aspect of the CMC review, the QOS has significantly decreased the time spent transcribing and summarizing information, thus leaving more time for the evaluation. QbR has also stimulated an increase in the number of fully electronic submissions, which save OGD time in processing the applications and increase efficiency for the reviewer by facilitating access to the information.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here